• SPX
  • $5,628.95
  • -0.07 %
  • -$4.14
  • DJI
  • $41,526.36
  • -0.23 %
  • -$95.73
  • N225
  • $36,203.22
  • -1.03 %
  • -$378.54
  • FTSE
  • $8,309.86
  • 0.38 %
  • $31.42
  • IXIC
  • $17,611.95
  • 0.11 %
  • $19.82
BioVie Inc. (BIVI) Stock Price, News & Analysis

BioVie Inc. (BIVI) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.91

-$0.22

(-7.13%)

Day's range
$2.87
Day's range
$3.11
50-day range
$2.07
Day's range
$4.77
  • Country: US
  • ISIN: US09074F2074
52 wk range
$2.07
Day's range
$58.2
  • CEO: Mr. Cuong Viet Do M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -16.86
  • Piotroski Score 2.00
  • Grade Overweight
  • Symbol (BIVI)
  • Company BioVie Inc.
  • Price $2.91
  • Changes Percentage (-7.13%)
  • Change -$0.22
  • Day Low $2.87
  • Day High $3.11
  • Year High $58.20

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 09/22/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.93
  • Trailing P/E Ratio -0.46
  • Forward P/E Ratio -0.46
  • P/E Growth -0.46
  • Net Income $-50,255,815

Income Statement

Quarterly

Annual

Latest News of BIVI

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.